BB-K8
BB-K8 Brand names, BB-K8 Analogs
BB-K8 Brand Names Mixture
- No information avaliable
BB-K8 Chemical_Formula
C22H43N5O13
BB-K8 RX_link
http://www.rxlist.com/cgi/generic3/amikacin.htm
BB-K8 fda sheet
BB-K8 msds (material safety sheet)
BB-K8 Synthesis Reference
H. Kawaguchi, T. Naito, Ger. pat. 2,234,315; H. Kawaguchi et al., U.S. pat. 3,781,268 (both 1973 to Bristol-Myers)
BB-K8 Molecular Weight
585.603 g/mol
BB-K8 Melting Point
203-204 oC
BB-K8 H2O Solubility
1.85E+005 mg/L
BB-K8 State
Solid
BB-K8 LogP
-9.048
BB-K8 Dosage Forms
IM infusion; IM injection
BB-K8 Indication
For short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter (Mima-Herellea) species.
BB-K8 Pharmacology
Amikacin is an aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.
BB-K8 Absorption
Rapidly absorbed after intramuscular administration
BB-K8 side effects and Toxicity
No information avaliable
BB-K8 Patient Information
BB-K8 Organisms Affected
Enteric bacteria and other eubacteria
